Alternating Hemiplegia |
Hemiplegia Alterans |
Clinical Trial: A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)
This study has been completed.
|
Purpose
To determine the relative clinical efficacy of zidovudine ( AZT ) plus didanosine (ddI), AZT plus zalcitabine ( ddC ), AZT alternating monthly with ddI, and AZT/ddI plus nevirapine in HIV-infected patients with advanced disease. The rapid emergence of resistant HIV strains has been observed in patients receiving monotherapy with a nucleoside analog or non-nucleoside reverse transcriptase inhibitor. Use of combination therapy with two nucleoside drugs or convergent combination therapy with two nucleosides and a non-nucleoside RT inhibitor may minimize the evolution of these resistant HIV strains. Since toxicity is a major problem in patients with advanced disease who are receiving combination nucleoside therapy, alternating the two drugs may provide a way of retaining several benefits of combination therapy while minimizing the increased toxicity.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Nevirapine Drug: Zidovudine Drug: Zalcitabine Drug: Didanosine | Phase II |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Double-Blind, Efficacy Study
Expected Total Enrollment: 1292
The rapid emergence of resistant HIV strains has been observed in patients receiving monotherapy with a nucleoside analog or non-nucleoside reverse transcriptase inhibitor. Use of combination therapy with two nucleoside drugs or convergent combination therapy with two nucleosides and a non-nucleoside RT inhibitor may minimize the evolution of these resistant HIV strains. Since toxicity is a major problem in patients with advanced disease who are receiving combination nucleoside therapy, alternating the two drugs may provide a way of retaining several benefits of combination therapy while minimizing the increased toxicity.
Patients are randomized to receive either AZT/ddC, AZT/ddI, AZT alternating monthly with ddI, or AZT/ddI/nevirapine. Patients are evaluated at week 0 and every 4 weeks thereafter for 2 years. Pharmacologic, virologic, and macroneurologic substudies will be conducted. Patients who are already enrolled on protocol ACTG 193 will be given the option of continuing on their originally assigned ACTG 193 therapy for an additional 6 months or undergoing re-randomization to one of the four treatment arms on ACTG 193A.
Eligibility
Ages Eligible for Study: 13 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria
Concurrent Medication: Required:
- PCP prophylaxis.
Allowed:
- Erythropoietin maintenance.
- G-CSF and GM-CSF.
- Prophylaxis for Mycobacterium avium intracellulare.
- Antifungal prophylaxis or treatment with specific drugs.
- Maintenance therapy for opportunistic infection.
- Over-the-counter medications or alternative therapies such as vitamins and herbs.
- Antibiotics as clinically indicated.
- Steroids for < 21 days for acute problems.
- Antipyretics, analgesics, allergy medication, antidepressants, sleep medications, oral contraceptives, or other appropriate medications.
Concurrent Treatment: Allowed:
Patients must have:
- Documented HIV infection.
- CD4 count <= 50 cells/mm3.
- Either no prior nucleoside therapy OR a history of prior nucleoside therapy in the absence of high-grade intolerance.
- Life expectancy of at least 6 months.
- Consent of parent or guardian if < 18 years of age.
- Normal chest x-ray at baseline or within 6 months prior to study entry in the absence of new pulmonary or cardiac symptoms (per 12/28/94 amendment).
NOTE:
- Patients who withdrew from protocol ACTG 193 therapy prior to activation of ACTG 193A are not eligible.
Exclusion Criteria
Co-existing Condition: Patients with the following symptoms or conditions are excluded:
- Abnormal baseline chest x-ray.
- New pulmonary or cardiac symptoms.
- Psychological or emotional problems sufficient to prevent compliance with study medication.
Concurrent Medication: Excluded:
- Systemic chemotherapy for malignancy.
- Acute or induction therapy for opportunistic infection.
- Antiretroviral drugs other than study drugs.
- Biological response modifiers.
- Erythromycin, phenytoin, phenobarbital, warfarin, or coumadin.
Patients with the following prior conditions are excluded:
- History of recurrent grade 3 or greater toxicity to AZT, ddI, or ddC on two or more occasions.
- Evidence of active pulmonary disease within 6 months prior to study entry.
- History of grade 3 or worse peripheral neuropathy.
- History of acute or chronic pancreatitis.
Prior Medication: Excluded:
- Prior nevirapine.
Excluded within 7 days prior to study entry:
- Acute therapy for opportunistic infection (maintenance therapy is permitted).
- Acute systemic therapy for a nonopportunistic infection or other medical condition.
- Antiretroviral drugs other than AZT, ddI, or ddC.
- Biological response modifiers.
- d4T therapy.
- Nucleosides other than those used in the study.
- Antibiotics containing clavulanate potassium.
Prior Treatment: Excluded:
- More than 4 units of blood in a 30-day period.
Active alcohol or drug abuse.
Location Information
Alabama
Univ of Alabama at Birmingham, Birmingham, Alabama, 35294, United States
California
Univ of California / San Diego Treatment Ctr, San Diego, California, 921036325, United States
Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, 94115, United States
San Francisco Gen Hosp, San Francisco, California, 941102859, United States
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco, California, 941102859, United States
Stanford Univ Med Ctr, Stanford, California, 943055107, United States
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, 900331079, United States
Huntington Memorial Hosp / Children's Hosp of Los Angeles, Pasadena, California, 91105, United States
Children's Hosp of Los Angeles, Los Angeles, California, 90027, United States
Harbor UCLA Med Ctr, Torrance, California, 90502, United States
San Mateo AIDS Program / Stanford Univ, Stanford, California, 943055107, United States
Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, 951282699, United States
Olive View Med Ctr, Sylmar, California, 91342, United States
Colorado
Mountain States Reg Hemo Ctr / Univ of Colorado, Denver, Colorado, 80262, United States
Univ of Colorado Health Sciences Ctr, Denver, Colorado, 80262, United States
Denver Dept of Health and Hosps, Denver, Colorado, 80262, United States
Rose Med Ctr, Denver, Colorado, 80262, United States
Connecticut
Yale Univ / New Haven, New Haven, Connecticut, 065102483, United States
District of Columbia
Howard Univ, Washington, District of Columbia, 20059, United States
Georgetown Univ Med Ctr, Washington, District of Columbia, 20007, United States
Whitman - Walker Clinic / Georgetown Univ Med Ctr, Washington, District of Columbia, 200072197, United States
HIV Ctr - District of Columbia Gen Hosp, Washington, District of Columbia, 200072197, United States
George Washington Univ / Hershey Med Ctr, Washington, District of Columbia, 20037, United States
Florida
Univ of Miami School of Medicine, Miami, Florida, 331361013, United States
Univ of South Florida, Tampa, Florida, 33612, United States
Hawaii
Univ of Hawaii, Honolulu, Hawaii, 96816, United States
Illinois
Northwestern Univ Med School, Chicago, Illinois, 60611, United States
Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, 60612, United States
Cook County Hosp, Chicago, Illinois, 60612, United States
Louis A Weiss Memorial Hosp, Chicago, Illinois, 60640, United States
Indiana
Indiana Univ Hosp, Indianapolis, Indiana, 462025250, United States
Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, 46202, United States
Kentucky
Univ of Louisville / East Tennesee Comprehensive Hem Ctr, Louisville, Kentucky, 40202, United States
Massachusetts
Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, 02114, United States
Beth Israel Deaconess - West Campus, Boston, Massachusetts, 02215, United States
Boston Med Ctr, Boston, Massachusetts, 02118, United States
Worcester Memorial Hosp / Med Ctr of Cntrl MA-Memorial, Worcester, Massachusetts, 01605, United States
Minnesota
Univ of Minnesota, Minneapolis, Minnesota, 55455, United States
St Paul Ramsey Med Ctr, St. Paul, Minnesota, 55101, United States
Hennepin County Med Clinic, Minneapolis, Minnesota, 55415, United States
Missouri
St Louis Regional Hosp / St Louis Regional Med Ctr, St. Louis, Missouri, 63112, United States
Nebraska
Univ of Nebraska Med Ctr, Omaha, Nebraska, 681985130, United States
New Hampshire
Dartmouth - Hitchcock Med Ctr / Med Ctr Cntrl Massachusetts, Lebanon, New Hampshire, 03756, United States
New Jersey
Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, 071032714, United States
Robert Wood Johnson Med School / Hershey Med Ctr, New Brunswick, New Jersey, 08903, United States
New York
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, 10461, United States
Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, 10461, United States
Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, 10461, United States
SUNY / State Univ of New York, Syracuse, New York, 13210, United States
Univ of Rochester Medical Center, Rochester, New York, 14642, United States
Mem Sloan - Kettering Cancer Ctr, New York, New York, 10021, United States
Bellevue Hosp / New York Univ Med Ctr, New York, New York, 10016, United States
Mount Sinai Med Ctr, New York, New York, 10029, United States
Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, 10465, United States
Cornell Univ Med Ctr, New York, New York, 10021, United States
Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, 10461, United States
Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, 10467, United States
Bronx Veterans Administration / Mount Sinai Hosp, Bronx, New York, 10468, United States
SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, 14215, United States
Mount Sinai Med Ctr / Hemophilia Treatment Ctr, New York, New York, 10029, United States
Beth Israel Med Ctr, New York, New York, 10003, United States
City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst, New York, 11373, United States
Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, 10467, United States
SUNY / Health Sciences Ctr at Brooklyn, Brooklyn, New York, 112032098, United States
Saint Clare's Hosp and Health Ctr, New York, New York, 10019, United States
North Shore Univ Hosp, Manhasset, New York, 11030, United States
North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, 10467, United States
Comprehensive Health Care Ctr / Bronx Municipal Hosp, Bronx, New York, 10461, United States
Columbia Presbyterian Med Ctr, New York, New York, 100323784, United States
Adirondack Med Ctr at Saranac Lake, Albany, New York, 122083479, United States
Mid - Hudson Care Ctr, Albany, New York, 122083479, United States
Albany Med College / Division of HIV Medicine A158, Albany, New York, 122083479, United States
Harlem Hosp Ctr, New York, New York, 10037, United States
North Carolina
Univ of North Carolina, Chapel Hill, North Carolina, 275997215, United States
Moses H Cone Memorial Hosp, Greensboro, North Carolina, 27401, United States
Ohio
Case Western Reserve Univ, Cleveland, Ohio, 44106, United States
Univ of Cincinnati, Cincinnati, Ohio, 452670405, United States
Columbus Children's Hosp, Columbus, Ohio, 432052696, United States
Med College of Ohio, Toledo, Ohio, 43699, United States
MetroHealth Med Ctr, Cleveland, Ohio, 441091998, United States
Univ of Kentucky Lexington, Cincinnati, Ohio, 45267, United States
Pennsylvania
Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, 19104, United States
Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, 191075098, United States
Girard Med Ctr, Philadelphia, Pennsylvania, 191046073, United States
Milton S Hershey Med Ctr, Hershey, Pennsylvania, 170330850, United States
Saint Michael's Med Ctr / Milton S Hershey Med Ctr, Hershey, Pennsylvania, 170330850, United States
South Carolina
Julio Arroyo, West Columbia, South Carolina, 29169, United States
Med Univ of South Carolina / UNC, Charleston, South Carolina, 29425, United States
Tennessee
Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee, 37920, United States
Meharry Med College, Nashville, Tennessee, 37203, United States
Texas
Univ Texas Health Science Ctr / Univ Texas Med School, Houston, Texas, 77030, United States
Univ of Texas Galveston, Galveston, Texas, 775550435, United States
Washington
Univ of Washington, Seattle, Washington, 981224304, United States
Wisconsin
Great Lakes Hemophilia Foundation, Wauwatosa, Wisconsin, 532130127, United States
Northern Wisconsin Hemophilia Ctr / Saint Vincent's Hosp, Green Bay, Wisconsin, 54301, United States
Puerto Rico
Univ of Puerto Rico, San Juan, 009365067, Puerto Rico
Henry WK, Study Chair
Kahn JO, Study Chair
Balfour HH, Study Chair
More Information
Click here for more information about Zidovudine
Click here for more information about Zalcitabine
Click here for more information about Didanosine
Click here for more information about Nevirapine
Publications
Henry K, Erice A, Tierney C, Balfour HH Jr, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):339-49.
Price RW, Yiannoutsos C, Zaborski L, Kmack A, Henry K, Tierney C, Clifford D. Neurological substudies of ACTG protocol 193A: quantitative neurological performance measures and treatment outcomes. Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:176 (abstract no 516)
Robinson P, Cotton D, Curry R, Henry K, Hall D, Myers M. Analysis of nevirapine (NVP) effect on clinical endpoints (CEs) of HIV progression or death in ACTG trial 193A. Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:210 (abstract no 700)
Henry K, Tierney C, Kahn J, Balfour H, Jiang Q, Kmack A, Fischl M. A randomized, double-blind, placebo-controlled study comparing combination nucleoside and triple therapy for the treatment of advanced HIV disease (CD4 less than or equal to 50/mm(3)). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:207 (abstract no LB6)
Coplan P, Nikas A, Saah A, Nessly M, Doll L, Leavitt R, Benson J, Guess H. No association observed between indinavir therapy for HIV/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:191 (abstract no 658)
Erice A, Tierney C, Balfour HH Jr, Liou S, Kahn JO, Henry WK. Virologlc effect of therapy with reverse transcriptase inhibitors (RTIs) in patients with AIDS and less than 50 CD4+ T cells per mm(3): a substudy of ACTG 193a. Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:204 (abstract no 662)
Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A, Henry K. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS. 1999 Sep 10;13(13):1677-85.
Record last reviewed: October 1996
Last Updated: April 7, 2005
Record first received: November 2, 1999
ClinicalTrials.gov Identifier: NCT00000781
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Alternating Hemiplegia (National Institute of Neurological Disorders and Stroke)

Not Signed In -

